An exploratory study on the efficacy, predictive markers and resistance mechanisms of Tislelizumab (anti-PD-1 antibody) combined with chemotherapy in the treatment of non-squamous non-small cell lung cancer patients with EGFR-sensitive mutations and previous EGFR-TKI treatment failure
Latest Information Update: 02 Dec 2020
Price :
$35 *
At a glance
- Drugs Tislelizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Dec 2020 New trial record